BiondVax Pharmaceuticals Ltd. (BVXV) Research

BiondVax Pharmaceuticals Ltd. is an Israeli-based biopharmaceutical company currently in its development stage. Its core mission involves the research, production, and market introduction of therapeutic products designed for the prevention and treatment of a range of infectious and other medical conditions. The company has established strategic licensing and collaboration agreements with prominent scientific institutions, notably the Max Planck Society and the University Medical Center Göttingen. These partnerships are geared towards the advancement and commercialization of nanosized antibodies (NanoAbs), including a specific candidate for COVID-19, and extending this technology to address various other disease indications. Founded in 2003, BiondVax maintains its corporate headquarters in Jerusalem, Israel.

Market snapshot

Symbol
BVXV
Price
$1.36
Day change
+0.74%
Market cap
$14.7M
P/E ratio
-19.62x
52-week range
0.63-11.49
Sector
Healthcare
Industry
Biotechnology

Peer companies

  • Aptose Biosciences Inc. (APTO)
  • Altamira Therapeutics Ltd. (CYTO)
  • Fresh Tracks Therapeutics, Inc. (FRTX)
  • Gamida Cell Ltd. (GMDA)
  • Hillstream BioPharma, Inc. (HILS)
  • Nabriva Therapeutics plc (NBRVF)
  • Neuphoria Therapeutics Inc. (NEUP)
  • Tricida, Inc. (TCDA)

Recent insider activity

  • MARGOLIN YAEL — trade (133200 shares) on 2023-01-01
  • MARGOLIN YAEL — trade (0 shares) on 2023-01-01
  • Laster Morris C — trade (133200 shares) on 2023-01-01
  • Laster Morris C — trade (0 shares) on 2023-01-01
  • Lowell George — trade (1000000 shares) on 2023-01-01

Open BiondVax Pharmaceuticals Ltd. (BVXV) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.